诺唯赞：与艺妙神州签署《细胞治疗合作项目合作开发协议》

Group 1 - The core viewpoint of the news is that NuoVation has signed a cooperation agreement with Beijing Yimiao Shenzhou Biopharmaceutical Co., Ltd. to develop a cell therapy project focused on Alzheimer's Disease, aiming to enhance early diagnosis and treatment options through technological innovation [1] - The collaboration will involve establishing a new biopharmaceutical company, with both NuoVation and Yimiao Shenzhou holding a 50% stake each, to facilitate further cooperation and specific business operations [1] - In 2024, NuoVation's revenue composition is projected to be 85.17% from research and experimental development, 14.66% from pharmaceutical manufacturing, and 0.17% from other businesses [1] Group 2 - As of the report, NuoVation's market capitalization is 9.7 billion yuan [2]